XFOR Stock Summary and Trading Ideas (X4 Pharmaceuticals | NASDAQ:XFOR)

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals trades on the NASDAQ stock market under the symbol XFOR.

As of February 6, 2026, XFOR stock price declined to $3.56 with 794,968 million shares trading.

XFOR has a beta of 0.85, meaning it tends to be less sensitive to market movements. XFOR has a correlation of 0.01 to the broad based SPY ETF.

XFOR has a market cap of $311.27 million. This is considered a Small Cap stock.

Last quarter X4 Pharmaceuticals reported $2 million in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-136,350 and exceeded earnings estimates by $.13.

In the last 3 years, XFOR traded as high as $77.25 and as low as $1.35.

The top ETF exchange traded funds that XFOR belongs to (by Net Assets): VTI, VXF, ITWO, URTY.

XFOR has underperformed the market in the last year with a price return of -78.4% while the SPY ETF gained +15.1%. XFOR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.6% and -3.8%, respectively, while the SPY returned +3.3% and +0.2%, respectively.

XFOR support price is $3.53 and resistance is $3.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XFOR shares will trade within this expected range on the day.